Belgian-based UCB is the ninth drug company to impose limits on 340B pricing involving contract pharmacies.

UCB Becomes Ninth Drug Manufacturer to Announce 340B Contract Pharmacy Limits

Belgian-based pharmaceutical manufacturer UCB this morning became the ninth drug company to impose limits on 340B pricing involving contract pharmacies.

Hospitals reported getting letters and an FAQ from UCB today by email announcing that, effective Dec. 13 and with respect to hospitals only, it “will provide products purchased at the 340B discounted price only to locations registered as a 340B covered entity or child site location. Pharmacies registered as a contract pharmacy will no longer be provided Bill To / Ship To replenishment orders.”

Belgian-based pharmaceutical manufacturer UCB this morning became the ninth drug company to impose limits on 340B pricing involving contract pharmacies.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report